GRANT AGREEMENT

The **parties** to this agreement are:

Novo Nordisk Denmark A/S
Att.: Christian Klyver Tikkanen
Ørestads Boulevard 108, 6.
2300 København S

Company registration no.
CVR No. 38180045

("Novo Nordisk")

Diabetesforeningen
Stationsparken 24, st. tv
2600 Glostrup

Company registration no.
CVR No. 35231528

("Recipient")

1. Purpose and nature of the grant

1.1 Recipient's request and healthcare purpose

The Recipient's request for financial support from Novo Nordisk for its activity Dashboard Diabetestal.nu is detailed in Attachment A. The Recipient shall use the grant only for the healthcare-related purpose of Diabetes awareness as described in Attachment A. The Recipient's purpose must not involve promotion of any pharmaceutical product.

1.2 Novo Nordisk's support

Novo Nordisk has decided the Recipient's request is worthy of support as part of Novo Nordisk's commitment to healthcare research.

Novo Nordisk agrees to grant to the Recipient the amount of 1.500.000 DKK to support the request.

Novo Nordisk will not make any non-financial transfers of value.

2. Start and end dates of this agreement

This agreement shall become effective as of date of last signatory and shall remain effective until sixty (60) days after the parties have fulfilled their obligations under it.

3. Recipient's duties

3.1 Inform Novo Nordisk of changes affecting the request

The Recipient shall inform Novo Nordisk promptly of changes affecting the nature, purpose, budget, participants or timing of the requested support. Novo Nordisk may increase, decrease, withdraw or demand full or partial repayment of the grant as a result of the changes. If Novo Nordisk demands full or partial repayment, the Recipient shall comply with the demand within 14 days.

3.2 Account for the activity within 1 month after completion

Within 1 month after completing the activity supported by the grant, the Recipient shall provide to Novo Nordisk a report or letter evidencing that the grant was used for its intended purpose. The Recipient may provide this documentation in the form of a letter or invoice with attachments, or other similarly substantiated written form acceptable to Novo Nordisk.

The Recipient shall also provide:

- photos, videos, articles, or other evidence demonstrating that the activity was carried out; written accounting of the reasonable, genuine and documented expenses for which the financial grant was used, with third-party invoices where applicable

3.3 Refund any unspent amounts

The Recipient shall refund to Novo Nordisk any amounts not spent for the requested purposes, as shown by the accounting and documentation.

3.4 Be responsible for proper conduct of the grant activity

The Recipient shall ensure that all activities covered by the Novo Nordisk grant are in compliance with Novo Nordisk's standards and applicable industry codes, including but not limited to:

- that the activity venue is reasonable and suitable for business meetings and only modest hospitality is offered;
- that travels are of reasonable standard within reasonable time before and after the grant activity;
- that the Novo Nordisk grant is not used for any tours, concerts, entertainment or other leisure or social activities;
- that advertising or trade names of medicinal products are not included in the educational content and materials used for the grant activity;
- that all speakers, facilitators, and chairpersons are experts in the professional fields relevant for the purpose of the grant; and
- that appropriate criteria for participation in the grant activity are applied.

3.5 Publicise Novo Nordisk as grant provider

The Recipient shall mention Novo Nordisk's name as a grant provider in publicity, advertising, announcements, articles, media releases or similar communications in relation to the supported activity.

3.6 Use Novo Nordisk branding only if approved

The Recipient may not use Novo Nordisk's logo, trademarks or other corporate identity marks or materials unless Novo Nordisk approves the use in advance in writing. Any use must comply with Novo Nordisk's Brand Manual (https://brandportal.novonordisk.com/).

3.7 Allow Novo Nordisk to publicise the grant with Recipient's logo

The Recipient hereby permits Novo Nordisk to use the Recipient's name, logo, trademarks or other organisational identity marks or materials in publicity, advertising, announcements, articles, media releases or similar communications concerning Novo Nordisk's grant.

4. General conditions

4.1 No conflict of interest

Recipient states it is not aware of any conflict of interest related to its acceptance of the grant. Recipient shall inform Novo Nordisk promptly if it discovers such a conflict of interest.

4.2 Compliance with law and ethics

When carrying out the activity supported by the grant, Recipient shall perform the activity in a proper, fair and balanced way and comply with all applicable laws, regulations, codes of practice, guidelines and industry standards, among others those related to bribery, corruption and unethical business practices. Recipient shall not give or receive bribes to obtain undue or improper advantage.

Novo Nordisk contract parties may securely and confidentially report suspected misconduct through the Novo Nordisk compliance hotline, **www.novonordisk.com/compliancehotline** Recipient shall inform its personnel about this compliance hotline where relevant.

Novo Nordisk will not be responsible for any deviation or departure from relevant laws, standards, regulations and guidelines ("Deviations") and Recipient will indemnify, defend and hold Novo Nordisk harmless against any claim or suit brought against Novo Nordisk due to such Deviations that are not due to any act or omission by Novo Nordisk.

4.3 Parties act independently

Recipient shall organise and conduct the supported activity independently from Novo Nordisk. Recipient shall incur all expenses and other financial commitments and take all other actions related to the supported activity in its own name and for its own account. By making the grant, Novo Nordisk does not assume any right or responsibility to influence the activity's content or conduct, or otherwise act on behalf of Recipient.

4.4 Grant is not an incentive

Novo Nordisk states and Recipient acknowledges that the grant is not an incentive or reward for the past, present or future willingness of Recipient, its employees or participants in Recipient's activities to prescribe, administer, recommend, purchase, pay for, reimburse, authorise, approve or supply, or to support in any other way, Novo Nordisk's products or services.

4.6 Parties may terminate upon breach

Either party may terminate this agreement with immediate effect upon a material breach by the other party.

4.7. Dispute resolution and applicable law

The parties shall use reasonable efforts to settle all matters in dispute amicably. Where settlement is not possible, disputes will be subject to the jurisdiction of the courts in the Recipient's location. The laws of that jurisdiction will apply to all disputed matters, to the exclusion of any rule that would refer the subject matter to another forum.

4.8. Parties' internal approvals

Each party states that the grant and this agreement have been approved by an authorised person according to the organisation's standard procedures.

5. Attachments

The following attachments are part of this agreement:

Attachment A: Recipient's request for support (application form, letter or email), with detailed program plan, timeline and budget

Attachment B: Invoice instructions for Recipient

Attachment C: Grants to HCOs and Patient Organisations: required public disclosures and handling of employee data

SIGNED BY:

Date: May 24, 2022

On behalf of Recipient:

DocuSigned by:
E8906967344243C...

Name: Tanja Thybo
Title: Ph.d

Date: maj 24, 2022

On behalf of Recipient:

DocuSigned by:
68C52187DA0647B...

Name: Claus Richter
Title: Direktør

Date: May 23, 2022

On behalf of Novo Nordisk:

DocuSigned by:
6086C4285774410...

Name: Christian Klyver Tikkanen
Title: Sr Market Access Manager & RareD Lead

Date: May 24, 2022

On behalf of Novo Nordisk:

DocuSigned by:
D6C3B77D06B64DC...

Name: Markus Hochmutch
Title: Director, MAPA & RareD

Date: May 24, 2022

On behalf of Novo Nordisk:

DocuSigned by:
961325E51CC942D...

Name: Kasper Mejlvang
Title: Generel Manager & VP

Attachment A to Grant Agreement

Recipient's request for support (application form, letter or email)

Til
Christian Klyver Tikkanen
Novo Nordisk Denmark A/S

Ansøgning om støtte til "Diabetestal.nu - Bred formidling af kvaliteten i behandlingen af diabetes i Danmark"

I Diabetesforeningen arbejder vi for at alle skal have den bedst mulige diabetesbehandling. Det er imidlertid svært at arbejde for en løbende forbedring, hvis man ikke let kan følge med i udviklingen og benchmarke kvaliteten af behandling. Vi tror på, at gennemsigtighed og let adgang til de nyeste kvalitetsdata vil forbedre kvaliteten af diabetesbehandlingen.

Diabetesforeningen arbejder derfor på at tilvejebringe og sammenstille information om dansk diabetes demografi og indikatorer for kvaliteten i behandlingen af diabetes i Danmark i en lettere tilgængelig form, der kan tilgås af alle, herunder borgere med diabetes, pårørende, behandlere, embedsværk i sundhedsvæsenet og politikere.

Formidlingen af kvaliteten i behandlingen af diabetes i Danmark skal opdateres 4 gange om året.
Alle brugere vil gratis kunne tilgå disse aggregerede data og informationer via et dashboard under Diabetesforeningens hjemmeside: **diabetestal.nu**.

Dashboardet vil bl.a. give mulighed for at følge udviklingen inden for en række proces- og resultatindikatorer samt give mulighed for at foretage en række analyser selv i dashboardet, som det kendes fra "knappen" i det svenske nationale diabetesregister (https://www.ndr.nu/#/knappen).

Ved at tilgå de aggregerede data og informationer, som gøres tilgængelig via Diabetesforeningens hjemmeside, vil borgere med interesse herfor kunne få svar på spørgsmål såsom:

- Hvor mange personer lever med diabetes (opdelt på type 1 og type 2), og hvor mange nye diagnosticeres hvert år?
- Hvor mange personer lever med senkomplikationer (fordelt på forskellige typer af senkomplikationer)?
- Hvor mange personer modtager farmakologisk behandling af forskellig karakter?
    - Forskellige typer af farmakologisk behandling for:
        - forhøjet blodglukose
        - forhøjet blodtryk
        - forhøjet kolesterol

- Hvor mange personer lever med velregulerede eller forhøjede niveauer (i forhold til standard behandlingsvejledninger)?
    - For:
        - blodglukose
        - blodtryk
        - kolesterol

Opgørelserne vil kunne fordeles på følgende:

- køn
- alder
- region
- hvor længe man har levet med diabetes (diabetes varighed).

Det vil ligeledes være muligt at vise tidstrends siden 2015, således at det er muligt at følge udviklingen.

Data og metode:

Data fra følgende nationale sundhedsregistre vil blive brugt:

1. CPR-registeret (CPR)
2. Landspatientregisteret (LPR ~ aktivitet på hospitaler)
3. Aktivitet i speciallægepraksis (DUSAS)
4. Lægemiddelstatistikregisteret (LSR)
5. Laboratoriedatabasens Forskertabel (LAB_F)
6. Sygesikringsregisteret (SSR)
7. Sygehusmedicinregisteret (SMR)
8. Dansk Diabetes Database (DDiD)

Metoden og projektet er nærmere beskrevet i bilag 1.

Perspektiv

I internationalt perspektiv foregår diabetesforskningen i Danmark på et meget højt niveau. Der er ikke alene fokus på udvikling af forbedrede lægemidler, forbedrede behandlingsmetoder og brug af ny teknologi (smart pens, sensorer til kontinuerlig måling af blodsukker, og insulinpumper), men også på kvalitetssikringsforskning, som er helt nødvendig for at måle effekten af indsatserne.

Hvert år udgives der en omfattende rapport fra Regionernes Kliniske Kvalitetesudvilklings Program (RKKP). Disse rapporter er typisk tilgængelige via link hos RKKP og Sundhed.dk, men er ofte svært tilgængelige for lægmand.

Med en let adgang til hyppigt opdaterede data er det forventningen, at alle interessenter på en let forståelig måde kan orientere sig om status og udvikling på diabetesområdet i Danmark, hvilket vil føre til en bedre mulighed for bl.a. behandlingsoptimering og at forbedre udnyttelsen af sundhedsvæsnets ressourcer, der som udgangspunkt altid er knappe.

Eksempler herpå:

- Politikere kan bruge informationerne som baggrundsmateriale og inspiration til politiske diskussioner om prioritering af ressourcerne på sundhedsområdet.

- Embedsværket kan bruge informationerne som baggrundsmateriale for prædiktioner af fremtidigt ressourceforbrug i sundhedsvæsenet inden for diabetesområdet.
- Sundhedsprofessionelle kan få inspiration til hvilke behandlingsmål, der evt. kræver særligt fokus i deres region.
- Brugere med diabetes (og deres pårørende) kan spejle deres egen situation i opgørelserne af de landsdækkende/regionale forhold, og få inspiration til samtaler om eget helbred med deres praktiserende læge eller speciallæge/diabetessygeplejerske på ambulatorium.

Diabetesforeningen er indgået i samarbejde med IQVIA om at udvikle et diabetes dashboard, som beskrevet ovenfor. For mere uddybende projektbeskrivelse, se bilag x.

Detailed program/research project plan, timelines and budget

Arbejdet starter **1. april 2022** og dasboard forventes at gå live i **oktober 2022.** Derefter vil projektet overgå til drift. Nærværende ansøgning omhandler udelukkende udviklingsprojektet.

Arbejdet udført af IQVIA koster **2.265.278 kr.** + moms. Hertil kommer interne ressourcer på 0,5 FTE, som dækkes af Diabetesforeningen. Se bilag 1.

Vi søger derfor Novo Nordisk Denmark A/S om et sponsorat på **1.500.000 kr.** til hjælp til finansiering af projektet.

Beløbet tillægges moms.

For yderligere information, se bilag 1.

Med venlig hilsen

Tanja Thybo

Tlf.: +45 41 91 88 11
tth@diabetes.dk

Forslag til en overordnet projektplan



Omkostninger – ved kvartalsvise opdateringer

Med anvendelse af studiepopulation fra RKKP

Aktiviteter	Udvikling 6 måneder	Drift år 1 4 data refresh	Drift år 2 4 data refresh	Drift år 3 4 data refresh	Total
Udvikling af teknisk løsning	1.426.668				1.426.668
Vedligeholdelse af teknisk løsning		179.578	175.987	172.395	527.960
Infrastruktur & licenser*	244.083	511.412	511.412	511.412	1.778.317
Dataplatform:					0
IQVIA	419.528	378.746	361.863	347.534	1.507.670
SDS	175.000	100.000	100.000	100.000	475.000
RKKP	0	0	0	0	0
Total	**2.265.278**	**1.169.736**	**1.149.262**	**1.131.340**	**5.715.615**

Attachment B to Grant Agreement

Invoice instructions for Recipient

Novo Nordisk requires a complete and correct invoice from the recipient before paying the grant amount.

Novo Nordisk will pay invoices only via electronic funds transfer to the Recipient's account.


INVOICE

INVOICE CONTENTS Any invoice that does not meet the criteria below will be returned for correction.
Recipient's information
Recipient's full company name and address (the company signing the Grant Agreement)
Bank account for electronic payment: account holder name, account number (IBAN), bank name and address, routing number or code (SWIFT/BIC in EU)
Invoice information
Invoice number or reference
Invoice date
Specification of the account entry type (invoice, credit note, etc.)
Grant information
Quantity and nature of the grant activity covered by the invoice
Date (if known) of the grant activity covered by the invoice
Grant amount payable and currency
Novo Nordisk information
Novo Nordisk's full company name and address (the company signing the Grant Agreement): Novo Nordisk Denmark A/S, Ørestads Boulevard 108, 6., 2300 København S
Novo Nordisk contact person's full name and initials: CTIK Christian Klyver Tikkanen
VAT or sales tax information (only where applicable by law)
VAT or other tax amount payable
VAT or other tax rate applied
Novo Nordisk company VAT number: 38180045
Send invoices or credit notes by email with attached pdf (no paper copy) to:
Novo Nordisk Denmark A/S

CJZY@novonordisk.com with a copy to Novo Nordisk contact person

Attachment C to Grant Agreement

Grants to HCOs and Patient Organisations: required public disclosures and handling of employee data

Novo Nordisk, as a member of EFPIA (the European Federation of Pharmaceutical Industries and Associations), is required to make public the details of payments or in-kind transfers made to Recipient.

Novo Nordisk will publish information relating to this Grant on Novo Nordisk's website (https://www.novonordisk.dk/about/etiske-regler.html). According to local regulations Novo Nordisk may in addition make this Grant Agreement publicly available.

The Recipient shall provide to Novo Nordisk upon request all information reasonably required for Novo Nordisk's compliance with legal and/or regulatory requirements for contracting, tracking and disclosing transfer of values (ToVs) to the Recipient.

Recipient will publish information on the Grant on the Recipient's webpage. The information will include the Grant amount and, if applicable, any in kind transfer, cf. the Danish Pharmaceutical Promotional Act (Reklamebekendtgørelsen) § 21. Publication must be made ensuring that support received from pharmaceutical companies is clearly separated. The information must be available on the Recipient's webpage no later than one (1) month after the Recipient received the Grant. The information must be publicly available for at least two (2) years.

Novo Nordisk hereby informs the Recipient that information about the Recipient is collected, used, stored, transferred and disclosed (collectively **"Processed"**) by or on behalf of Novo Nordisk. Novo Nordisk processes information such as name, business address, contact details, nature of relationship with Novo Nordisk, tax number, unique identifier, and any ToVs from Novo Nordisk to the Recipient.

Whenever the Recipient shares with Novo Nordisk information about its employees, the Recipient shall inform the employees that their information is being shared and provide them with all information required under Article 13 and 14 of the General Data Protection Regulation, if applicable, and under other applicable data privacy laws. The Recipient shall indemnify Novo Nordisk and any affiliate of Novo Nordisk against all claims, expenses, losses and damages or liabilities arising from the Recipient's breach of its obligations to provide this information to its employees.